The stocks in the S&P 500, for instance, average a yield of just 1.3%. It would mean you have to invest around $77,000 in S&P ...
A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...
Shares of Bristol Myers Squibb Co. BMY shed 3.04% to $58.76 Tuesday, on what proved to be an all-around positive trading ...
Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.
In an amicus brief, several advocacy groups warned that letting the lawsuit proceed past a motion to dismiss could open the ...
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $60.6 which represents a slight increase of $0.93 or 1.56% from the prior close of $59.67. The stock opened at $60.08 and ...
Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of ...
1d
Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...
Bristol-Myers Squibb’s $2.6B pension risk transfer lawsuit is ‘frivolous,’ say industry groups
The ERISA Industry Committee, along with two other industry groups, is seeking the dismissal of the drugmaker’s PRT lawsuit ...
Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...
Could the largest market for the new schizophrenia drug xanomeline and trospium chloride (Cobenfy) be in Alzheimer's disease ...
We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback